National Institutes of Health
Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
Early Immune System Development and Ontogeny (R01 Clinical Trial Optional) is a funding opportunity from National Institutes of Health, up to $40.0M, closing November 5, 2028.
Overview
Early Immune System Development and Ontogeny (R01 Clinical Trial Optional) The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and…